Latest news with #Parimala


The Hindu
29-06-2025
- General
- The Hindu
Raghavendra Mutt seer initiates construction of golden chariot in Udupi
Sri Subhudendra Tirtha Swamiji of Mantralaya Raghavendra Mutt initiated construction of Parthasarathy golden chariot of Paryaya Puthige Mutt for the deity Sri Krishna in Udupi on Sunday (June 29, 2025). To symbolise the event, Sri Subhudendra Tirtha presented Sri Sugunendra Tirtha Swamiji, the Paryaya Puthige mutt seer, a gold necklace for the deity in the morning. A formal launch ceremony was held at the Rajangana in the Sri Krishna Mutt premises around noon, where the Raghavendra Mutt seer was felicitated. Speaking on the occasion, Sri Sugunendra Tirtha said Parthasarathy chariot was a memorial to the Koti Bhagawad Gita Parayana Yajna taken up in his present Gita Paryaya. 'It is appropriate that seer of Raghavendra Mutt, which is known for its prosperity, initiated the construction of the golden chariot. We hope construction of the new chariot will be completed quickly,' Puthige Mutt seer said. Sri Subhudendra Tirtha said it was in the Krishna Mutt that Sri Raghavendra Swamiji wrote his important 'Parimala', the revered theological work, 400 years ago. 'The place I am sitting (in the Mutt) is one where Raghavendra Swamiji had the realisation that the lord inside him was the same as the one he is seeing in front of his eyes'. The Raghavendra Swami Mutt will support all actions of Puthige Mutt in spreading the tenets of Bhagawad Gita and of Madhawacharya philosophy, the seer said. The new chariot is being constructed to have chariot ceremonies throughout the year in Krishna Mutt premises, the seer said. Sri Subhudendra Tirtha was ceremonially welcomed by Sri Sugunendra Tirtha into the Krishna Mutt. The two seers and Sri Susreendra Tirtha Swamiji, the junior seer of Puthige Mutt, spent some time at the Madhvasarovara, which is adjoining the Krishna Mutt.


Time of India
22-06-2025
- Health
- Time of India
South India's longest-know Car-T therapy survivors in Bengaluru return to daily life
Bengaluru: Two of South India's longest-known survivors of Car-T cell therapy are now regaining strength and embracing their return to everyday life. Rehan, 43, and Parimala, 66, (names changed) shared their emotional and inspiring recovery journeys with reporters during an event hosted by Narayana Health City last week. Rehan, who was diagnosed with stage 3 follicular lymphoma, said he had exhausted all conventional treatment options before turning to Car-T therapy, a type of treatment that uses the patient's own genetically modified T-cells. "I was mentally prepared — both my parents were cancer patients. I didn't need counselling. I was ready to fight for the sake of my family," he said. Having endured multiple rounds of chemotherapy and several relapses, Rehan opted for Car-T therapy in Nov 2022. Today, he is in his 31st month of remission. "Unlike chemotherapy, Car-T didn't have the severe side-effects. No hair loss, no nausea, no psychological trauma from physical changes. I was immunocompromised, yes, and had to avoid crowds, but I've got back to 80-85% of my pre-cancer energy levels," he said. The treatment involved two cycles of palliative chemotherapy followed by a 30-day hospital stay, during which he received the Car-T cell infusion and was kept under observation. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like One of the Most Successful Investors of All Time, Warren Buffett, Recommends: 5 Books for Turning... Blinkist: Warren Buffett's Reading List Click Here Undo PET CT scans have since consistently shown that the disease remains in remission. "There's no daily medication now. I work in sales and marketing, and live a fairly normal life," he added. He did, however, recall a mild setback: "I caught an infection during Umrah (a non-mandatory Islamic pilgrimage to Mecca), but it was quickly managed by the hospital." Parimala's story, as translated from Tamil by her son-in-law, painted a similarly uplifting picture. Once struggling to move or eat during chemotherapy, she now walks unaided, eats normally, and even assists her daughter in cooking. "She regained the weight she lost during chemo and can now eat a full diet, no longer limited to liquids," he said. Diagnosed with lymphoma in 2018, Parimala initially underwent six chemotherapy cycles in Coimbatore, relapsing two years later and enduring another six cycles before opting for Car-T therapy. Dr Sharat Damodar, senior consultant haematologist and lead researcher at Narayana Health City, noted that both patients were among over 20 enrolled in the centre's Immunil Car-T therapy trial launched three years ago. "If I look back at South India, these are the longest surviving patients post Car-T therapy. We're preparing to launch myeloma trials next, along with second-phase trials for leukaemia and lymphoma across more centres," he said. Dr Nitin Manjunath, director at Narayana Health City, said: "We're in discussions with insurance providers and govt bodies, including the Karnataka govt, to include Car-T therapy in reimbursement schemes. All treatments at Narayana are currently covered under Narayana Health Insurance," he added.